TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Sakar Healthcare Limited
SAKAR

Sakar Healthcare Limited Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 65/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,135.85

Change

+7.3 (0.65%)

Open

₹1,125.1

Prev. Close

₹1,128.55

Day High

₹1,189.5

Day Low

₹1,125.1

Volume Analysis

Traded

99,278

Delivered

45,065

Delivery %

45.39%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (28.0%)

Weaknesses (2)

  • •Low return on equity (9.99%)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (26.9%)
  • •Strong 3-year revenue growth (23.6%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,239.6 ₹1,214.55 ₹1,175.2 ₹1,150.15 ₹1,110.8 ₹1,085.75 ₹1,046.4
Fibonacci ₹1,214.55 ₹1,189.95 ₹1,174.75 ₹1,150.15 ₹1,125.55 ₹1,110.35 ₹1,085.75
Camarilla ₹1,153.56 ₹1,147.66 ₹1,141.75 ₹1,150.15 ₹1,129.95 ₹1,124.04 ₹1,118.14

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+179.15%

1 Week

-1.95%

1 Month

+29.71%

3 Months

+35.53%

6 Months

+120.28%

1 Year

+218.61%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹212.14

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

10.19%

Net margin 13.24% × asset turnover 0.52x × equity multiplier 1.48x

Company Overview

Sector

Healthcare

Market Cap

₹2,527 Cr

P/E (TTM)

70.0

ROE

9.99%

Book Value

₹146.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Sakar Healthcare Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (28.0%); low return on equity (9.99%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

93

Valuation

1

Cash Flow

62

Corporate Governance

43

Momentum

89

Institutional Ownership

48

Business Quality

71

Risk & Volatility

59

Liquidity

53

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 23.1% CAGR over last 5 years
  • −Stock is trading at 7.79 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 7.50% over last 3 years.
  • −Promoter holding has decreased over last 3 years: -8.20%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Appointment 22 Sep

Shareholders approved M/s. Kashyap R. Mehta & Partners as Secretarial Auditors for five years from FY2026-27.

Shareholders meeting 22 Sep

Sakar Healthcare’s 22nd AGM on 22 September 2026 passed all four resolutions.

Shareholders meeting 22 Sep

Sakar Healthcare held its 22nd AGM on September 22, 2026; approved FY26 accounts, director reappointment, and auditor appointments.

Analysts/Institutional Investor Meet/Con. Call Updates 14 Sep

Sakar Healthcare to hold analyst and investor plant visit on September 17-18, 2026.

Analysts/Institutional Investor Meet/Con. Call Updates 14 Sep

Sakar Healthcare will host analyst and investor plant visits and management meetings on September 17-18, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 39 34 37 43 41 43 43 50 53 58 70 71 73
Expenses + 30 25 28 32 30 31 32 35 40 46 52 45 52
Operating Profit 9 9 9 11 11 12 12 16 13 11 19 26 21
OPM % 23.0% 27.0% 24.0% 25.0% 26.0% 27.0% 27.0% 31.0% 24.0% 20.0% 26.0% 37.0% 29.0%
Other Income + 2 1 0 1 0 0 0 0 0 1 1 0 2
Interest 2 2 2 2 1 2 1 4 2 2 2 2 2
Depreciation 5 4 4 5 5 5 5 5 6 6 6 6 7
Profit before tax 4 4 3 5 5 5 5 6 5 5 11 18 15
Tax % 28.0% 13.0% 31.0% 35.0% 49.0% 6.0% 17.0% 8.0% 13.0% 15.0% 6.0% 39.0% 29.0%
Net Profit + 3 4 2 3 2 5 5 6 5 5 10 11 10
EPS in Rs 1 2 1 1 1 2 2 3 2 2 5 5 5
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 83 95 128 133 153 178 251 272
Expenses + 63 72 99 100 115 128 182 195
Operating Profit 20 23 29 33 38 50 69 77
OPM % 24.0% 24.0% 23.0% 25.0% 25.0% 28.0% 27.0% 28.0%
Other Income + 2 1 2 5 3 1 2 3
Interest 2 2 3 6 8 9 8 7
Depreciation 7 8 10 15 18 21 24 25
Profit before tax 12 13 19 17 16 22 40 49
Tax % 21.0% 19.0% 20.0% 24.0% 27.0% 19.0% 23.0% —
Net Profit + 10 11 15 13 12 18 30 36
EPS in Rs 6 7 9 7 5 8 14 16
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 66 83 110 154 241 264 302
Borrowings + 17 43 93 119 79 86 71
Other Liabilities + 17 37 47 44 47 43 86
Total Liabilities 115 178 268 336 389 415 481
Fixed Assets + 66 69 205 267 314 309 326
CWIP 13 49 1 6 0 17 4
Investments 0 0 7 3 0 0 0
Other Assets + 36 60 55 60 74 90 151
Total Assets 115 178 268 336 389 415 481
Equity Capital 15 16 17 19 22 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 19 15 36 33 24 34 49
Cash from Investing Activity + -22 -47 -90 -74 -52 -31 -28
Cash from Financing Activity + 3 32 55 41 27 -3 -21
Net Cash Flow 0 0 0 0 0 0 0
CFO/OP 110 67 120 113 72 73 77
Free Cash Flow -4 -32 -62 -49 -35 2 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.15% → 52.52%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 21.0% 22.47% 22.71% 22.71% 22.8% 21.96% 21.85% 22.48% 22.41% 22.73% 22.87% 23.98%
Promoters 54.15% 53.15% 53.15% 53.15% 53.15% 53.58% 53.58% 52.86% 52.86% 52.86% 52.86% 52.52%
FII 14.03% 13.76% 13.52% 13.52% 13.42% 13.58% 13.61% 13.41% 13.31% 13.05% 12.94% 12.13%
DII 10.82% 10.62% 10.62% 10.62% 10.62% 10.88% 10.97% 11.25% 11.43% 11.36% 11.32% 11.37%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sakar Healthcare Limited (this stock) 2,527 70.0 7.78 9.99%
Shukra Pharmaceuticals L 2,465 72.6 27.27 28.9%
Fischer Medical Venture L 2,401 98.1 5.85 8.91%
Beta Drugs Limited 2,400 52.6 8.98 18.8%
Vimta Labs Limited 2,679 44.1 7.76 13.5%
Dishman Carbo Amcis Ltd 2,718 150.0 0.41 1.58%
Hikal Limited 2,731 64.4 2.28 2.21%

Which Mutual Funds Hold Sakar Healthcare Limited?

Frequently Asked Questions about Sakar Healthcare Limited

Community Sentiment

What are other investors saying about Sakar Healthcare Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.